Oncobit AG, a precision oncology company developing next-generation cancer monitoring solutions, has completed more than CHF 1.9 million in a new financing round. The funds will, among other activities, flow into advancing clinical developments and expansion into new markets.

精准肿瘤学公司Oncobit AG已完成超过190万瑞士法郎的新一轮融资。这笔资金将用于推进临床开发并拓展新市场等各项活动。

Supported by both existing and new investors, including private business angels and strategic partner ID Solutions (IDS), this new capital increase in Oncobit strengthens the company’s financial position and provides the resources needed to advance ongoing clinical validation, regulatory, and commercialization activities.

现有投资者和新投资者，包括私人企业天使投资人和战略合作伙伴ID解决方案（IDS），支持了Oncobit的这次增资，增强了公司的财务状况，并提供了推进正在进行的临床验证、监管和商业化活动所需的资源。

The funds will enable Oncobit to accelerate its expansion into additional cancer indications and new markets, building on its IVDR and ISO 13485 certifications and its growing network of clinical and industry partners..

这笔资金将使Oncobit能够加速扩展到更多的癌症适应症和新市场，基于其IVDR和ISO 13485认证以及不断扩大的临床和行业合作伙伴网络。

“We are very pleased to have successfully completed this financing round with the continued support of our investors and the addition of new shareholders”, said Claudia Scheckel, CEO of Oncobit AG. “This investment underscores the confidence in our technology and team and allows us to continue executing on our mission to make precision cancer monitoring broadly accessible.”.

“我们非常高兴在现有投资者的持续支持和新股东的加入下成功完成了这一轮融资，” Oncobit AG 首席执行官 Claudia Scheckel 表示。“这笔投资彰显了对我们技术和团队的信心，并使我们能够继续执行我们的使命，让精准癌症监测得到广泛应用。”

Established in 2018 as spinoff from the University of Zurich, Oncobit has developed a scalable, data-driven cancer monitoring platform based on the quantitative and highly sensitive detection of cancer markers in liquid biopsies. By focusing on the most clinically impactful biomarkers and leveraging cutting-edge technology, the company provides cost-effective and time-efficient solutions that enable close monitoring of a patient’s cancer and support optimized therapy management..

2018年从苏黎世大学分拆出来成立的Oncobit公司，开发了一个可扩展的、数据驱动的癌症监测平台，该平台基于对液体活检中癌症标志物的定量和高灵敏度检测。通过专注于临床上最有影响力的生物标志物，并利用尖端技术，该公司提供了经济高效且省时的解决方案，能够密切监测患者的癌症状况并支持优化治疗管理。

Its cloud-based data analysis and interpretation software, trained on both healthy and patient datasets, ensures robust and standardized result reporting. Today, Oncobit’s diagnostic solutions are trusted by a growing number of pharmaceutical companies, clinical laboratories, and hospital institutions..

其基于云的数据分析和解释软件，通过对健康人群和患者数据集的训练，确保了结果报告的稳健性和标准化。如今，Oncobit的诊断解决方案正受到越来越多制药公司、临床实验室和医院机构的信任。

(Press release/RAN)

（新闻稿/随机接入网络）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送